A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial-Reference-Cited by-同舟云学术

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial

Published:2017-09 Issue: Volume:191 Page:37-46
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Hayer Manvir K.,Edwards Nicola C.,Slinn Gemma,Moody William E.,Steeds Rick P.,Ferro Charles J.,Price Anna M.,Andujar Cecilio,Dutton Mary,Webster Rachel,Webb David J.,Semple Scott,MacIntyre Iain,Melville Vanessa,Wilkinson Ian B.,Hiemstra Thomas F.,Wheeler David C.,Herrey Anna,Grant Margaret,Mehta Samir,Ives Natalie,Townend Jonathan N.

Funder

British Heart Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization;Go;N Engl J Med,2004

2. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis;Matsushita;Lancet,2010

3. Trends in prevalence of chronic kidney disease in the United States;Murphy;Ann Intern Med,2016

4. Arterial disease in chronic kidney disease;Moody;Heart,2012

5. Aortic distensibility and arterial–ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction;Edwards;Heart,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease;Clinical Journal of the American Society of Nephrology;2021-08-30

2. Mineralocorticoid receptor antagonists in patients with chronic kidney disease;Pharmacology & Therapeutics;2021-03

3. Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease;JACC: Cardiovascular Imaging;2020-11

4. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease;Cochrane Database of Systematic Reviews;2020-10-27

5. Pharmacological interventions for heart failure in people with chronic kidney disease;Cochrane Database of Systematic Reviews;2020-02-27